Single agent gemcitabine chemotherapy in dogs with spontaneously occurring lymphoma

Journal of Veterinary Internal Medicine

Volumn 20, Issue 6, 2006, Pages 1384-1388

  Turner, Avenelle I ^a,e   Hahn, Kevin A ^a,e   Rusk, Anthony ^b   Gamblin, Rance M ^c   Cosgrove, Sallie B ^d   Griffice, Kelly ^a   Khanna, Chand ^b  

^a Gulf Coast Veterinary Oncology   (United States)

^b Animal Cancer Institute LLC   (United States)

^c Metropolitan Veterinary Hospital   (United States)

^d ELANCO ANIMAL HEALTH   (United States)

^e Fifth Avenue Veterinary Specialists ^*  (United States)

Author keywords

Anticancer agents; Chemotherapy; Gemzar; Lymphosarcoma; Nucleoside analog

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CANCER STAGING; CLINICAL TRIAL; DOG; DOG DISEASE; DRUG EFFECT; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MALE; MULTICENTER STUDY; NEUTROPHIL; PROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DOG DISEASES; DOGS; FEMALE; INFUSIONS, INTRAVENOUS; LYMPHOMA; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUTROPHILS; PLATELET COUNT; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

EID: 33845771202     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2006)20[1384:SAGCID]2.0.CO;2     Document Type: Article

References (34)

1. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: Metabolism, mechanism of action, and self potentiation. Semin Oncol 1995;22(4 Suppl 11):3-10.
2. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: Mechanisms of drug resistance and reversal strategies. Leukemia 2001;15:875-890.
3. Cozzi PJ, Bajorin DF, Tong W, et al. Toxicity and pharmacokinetics of intravesical gemcitabine: A preclinical study in dogs. Clin Cancer Res 1999;5:2629-2637.
4. Shipley LA, Brown TJ, Cornpropst JD, et al. Metabolism and disposition of gemcitabine and oncolytic deoxycytidine analog, in mice, rats and dogs. Drug Metab Dispos 1992;20(6):849-855.
5. Feliu J, Martin G, Madronal C, et al. Combination of low-dose cisplatin and Gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2003;52(3):247-252.
6. Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly Gemcitabine in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 1994;12(9):1821-1826.
7. Manegold C, Zatloukal P, Krejcy K, et al. Gemcitabine in non-small cell lung cancer (NSCLC). Invest New Drugs 2000;18(1):29-42.
8. Berlin JD, Rothenberg ML. Chemotherapeutic advances in pancreatic cancer. Curr Oncol Rep 2003;5(3):219-226.
9. Karasek P, Skacel T, Kocakova I, et al. Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: A prospective observational study. Expert Opin Pharmacother 2003;4(4):581-586.
10. Burris III HA, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as a first-line therapy for patients with advanced pancreas cancer: A randomized trial 1997;15(6):2403-2413.
11. Bass AJ, Gockerman JP, Hammett E, et al. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol 2002;20(13):2995-3000.
12. Johnson SA. Nucleoside analogues in the treatment of haematological malignancies. Expert Opin Pharmacother 2001;2(6):929-943.
13. Nabhan C, Krett N, Gandhi V, et al. Gemcitabine in hematologic malignancies. Curr Opin Oncol 2001;13(6):514-521.
14. Dumontet C, Morschhauser F, Solal-Celigny P, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low grade non-Hodgkin's lymphoma. Br J Haematol 2001;113(3):772-778.
15. Fossa A, Santoro A, Hiddemann W, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999;17(12):3786-3792.
16. Chau I, Watkins D, Cunningham D. Gemcitabine and its combinations in the treatment of malignant lymphoma. Clin Lymphoma 2002;3(3):97-104.
17. Fuchs CS, Clark JW, Ryan DP, et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002;15;94(12):3186- 3191.
18. Sternberg CN. Gemcitabine in bladder cancer. Semin Oncol 2000;27(Suppl 2):31-39.
19. D'Agostino G, Amant F, Berteloot P. Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003;88(3):266-269.
20. Rossi E, Perrone F, Labonia V, et al. Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? A single-center phase 2 study. Oncology 2003;64(4):479-480.
21. Agelaki S, Karyda E, Kouroussis Ch, et al. Gemcitabine plus irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: A multicenter phase II study. Oncology 2003;64(4):477-478.
22. Lobo F, Virizuela JA, Dorta FJ, et al. Gemcitabine/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: Results of a phase II trial. Clin Breast Cancer 2003;4(1):46-50.
23. Lawrence TS, Eisbruch A, McGinn CJ. Radiosensitization by Gemcitabine. Oncology (Williston Park) 1999;13(10 Suppl 5):55-60.
24. Kosarek CE, Kisseberth WC, Gallant SL, et al. Clinical evaluation of Gemcitabine with spontaneous occurring malignancies. J Vet Intern Med 2005;19:81-86.
25. LeBlanc AK, LaDue TA, Turrel JM, et al. Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: A veterinary radiation therapy oncology group pilot study. Vet Radiol Ultrasound 2004;45(5):466-470.
26. Owen LN. TNM classification of tumors in domestic animals. Geneva World Health Organization Bulletin, 1st ed, 1980.
27. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):649-655.
28. Okuno S, Edmonson J, Mahoney M, et al. Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002;15;94(12):3186-3191.
29. Abbruzzese JL, Gruenwals R, Weeks EA, et al. A phase one clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9(3)1 9:491-498.
30. Frazier DL, Price GS. Use of body surface area to calculate chemotherapeutic drug dose in dogs: II. Limitations imposed by pharmacokinetic factors. J Vet Intern Med 1998;12(4):272-278.
31. Price GS, Frazier DL. Use of body surface area (BSA)-based dosages to calculate chemotherapeutic drug dose in dogs: I. Potential problems with current BSA formulae. J Vet Intern Med 1998;12(4):267-271.
32. Gasper PW. The hematopoietic system. In: Feldman BF, Zinkl JG, Jain NC, eds. Schalm's Veterinary Hematology. Philadelphia, PA: Lippincott, Williams and Wilkins; 2000:63-68.
33. D'Agostino G, Ferrandina G, Ludovisi M. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer 2003;6;89(7):1180-1184.
34. Smith JA, Brown J, Martin MC, et al. An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines. Gynecol Oncol 2004;92(1):314-319.